CC-90009

DRUG3 trials

Sponsors

Celgene

Conditions

Healthy VolunteerLeukemia, Myeloid, AcuteMyelodysplastic Syndromes

Phase 1

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

TerminatedNCT02848001

CelgeneLeukemia, Myeloid, Acute, Myelodysplastic Syndromes

Start: 2016-11-14End: 2024-04-11Updated: 2025-06-12

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

CompletedNCT04297124

CelgeneHealthy Volunteer

Start: 2020-03-11End: 2021-06-04Updated: 2021-12-17

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

TerminatedNCT04336982

CelgeneLeukemia, Myeloid, Acute

Start: 2020-08-05End: 2024-04-05Updated: 2024-05-31

Related Papers

Abstract 1673: Discovery of potent, selective, and orally bioavailable GSPT1 degraders and their pre-clinical anti-tumor activity in acute myeloid leukemia and solid tumors

Cancer Research2023-04-042 citations

Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models

Blood2021-11-058 citations

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Blood2020-11-16206 citations

Abstract 2048: Discovery of induction and release of IL-1b are unique and on-target effects of GSPT1 degradation that provide potential mitigation strategies to hypotension in the CC-90009-AML-001 phase 1 trial

Cancer Research2020-08-153 citations

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood2019-11-1330 citations

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)

Blood2019-11-1325 citations

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Blood2019-11-1311 citations

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Blood2019-11-1311 citations

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Blood2019-11-138 citations